You are here

TKIs in CML Linked With Vascular Events

sandy craine's picture
Submitted by sandy craine on Sat, 20/02/2016 - 5:40pm

Treatment with the BCR-ABL tyrosine kinase inhibitors (TKIs) dasatinib, nilotinib, and ponatinib was associated with increased risk for vascular occlusive events in patients with chronic myeloid leukemia (CML) compared with imatinib, according to the results of a meta-analysis published in JAMA Oncology.

MTSS1 Protein May Act As Tumor Suppressor, Downregulated in CML

sandy craine's picture
Submitted by sandy craine on Sat, 20/02/2016 - 5:30pm

 

“Genetically, disease progression is associated with the acquisition of further chromosomal aberrations or mutations,” wrote study authors led by Mirle Schemionek, PhD, of University Hospital RWTH Aachen in Germany. “At the epigenetic level, DNA promoter methylation of specific genes, often tumor suppressors, has been associated with disease progression.”

Cell marker found for leukemia-initiating capacity in chronic myelogenous leukemia

sandy craine's picture
Submitted by sandy craine on Thu, 18/02/2016 - 2:45pm

University of Alabama at Birmingham researchers have found a marker on blood cells that may help the most pressing problem in chronic myelogenous leukemia, or CML, today — an inability to get patients off treatment.

At 5 Years, Nilotinib Offers Benefit Over Imatinib in CML

sandy craine's picture
Submitted by sandy craine on Thu, 11/02/2016 - 5:45pm

Five-year results of the randomised phase III ENESTnd trial show a positive risk-benefit profile for nilotinib in patients with chronic myeloid leukaemia (CML) in chronic phase (CP), as compared to imatinib. Cardiovascular risk does seem to be slightly raised with nilotinib, but improvements in CML disease control likely outweigh those risks. -

Government responds to Cancer Drugs Fund petition on blood cancer

sandy craine's picture
Submitted by sandy craine on Tue, 22/12/2015 - 3:03pm

As a member of the Blood Cancers Alliance (BCA), an informal coalition of charities representing the blood cancer community, Myeloma UK wrote an open letter to The Times newspaper on the Cancer Drugs Fund and the removal of blood cancer drugs from the list. 

International CML Foundation- November 2015 Newsletter

sandy craine's picture
Submitted by sandy craine on Mon, 21/12/2015 - 5:56pm

The International CML Foundation (iCMLf) is a Foundation established by a group of leading hematologists with a strong interest in CML. The mission of the iCMLf is to improve the outcomes for patients with CML globally. The Foundation is registered as a charitable organisation in England and Wales but its charter is global. Its aims are to foster and coordinate global clinical and research collaborations and to improve clinical practice and disease monitoring in CML, especially in emerging economic regions.

Pages